The rising government initiatives and funding for drug discovery and related research programs also contribute to market growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increased advancement of imaging techniques for the diagnostic purpose of osteonecrosis is also driving the market's growth in the forecasted period.
Access Full Report @ https://www.databridgemarketresearch.com/reports/us-osteonecrosis-market
Data Bridge Market Research analyses that the osteonecrosis market is expected to grow at a CAGR of 5.9% from 2023 to 2030 and reach USD 843,039.67 thousand by 2030. In 2023, the disease-type segment is expected to dominate the market due to the increasing number of road accidents causing traumatic injuries causing osteonecrosis in the U.S.
Key Findings of the Study
Increasing Consumption of Steroids and Related Drugs
The consumption of steroids and related drugs has risen and emerged as a significant driver for the U.S. osteonecrosis market. Osteonecrosis, also known as avascular necrosis, is a condition characterized by the death of bone tissue due to reduced blood supply. Steroids, such as corticosteroids, are widely prescribed for various medical conditions and have been identified as a significant risk factor for osteonecrosis. The increasing consumption of steroids and related drugs in the U.S. has implications for osteonecrosis' prevalence, diagnosis, and treatment. Steroids, when used for prolonged periods or in high doses, can disrupt the balance of bone metabolism and impair blood flow to the bone tissue.
Hence, the increasing consumption of steroids and related drugs represents a significant driver for the U.S. osteonecrosis market.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in Thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Traumatic, Non-Traumatic, and Idiopathic), Type (Diagnosis, and Treatment), Stages (Stage 1, Stage 2, Stage 3, and Stage 4), Location (Osteonecrosis of Hip/Femoral Head Osteonecrosis, Osteonecrosis of the Knee, Osteonecrosis of the Shoulder, Osteonecrosis of the Talus, Osteonecrosis of the Lunate, Osteonecrosis of the Scaphoid, and Others), Drug Type (Branded and Generic), Prescription (Over the Counter Drugs and Prescribed Drugs), Gender (Male and Female), Age (Children, Adult, and Geriatric), End User (Hospitals, Specialty Clinics, Orthopedic Clinics, Ambulatory Centers, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Country Covered
|
U.S.
|
|
Market Players Covered
|
Sciegen Pharmaceuticals (US), Almatica Pharma (US), Dr. Reddy's Laboratories Ltd.(India), Bayer AG (Germany), Pfizer Inc.(US), Haleon Group of Companies (UK), Zimmer Biomet (US), Stryker (US), Teva Pharmaceuticals USA, Inc. (Subsidiary of Teva Pharmaceutical Industries Ltd.) (USA), and Arthrex, Inc. (US), among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The U.S. osteonecrosis market is categorized into ten notable segments such as disease type, type, stages, location, drug type, prescription, gender, age, end user, and distribution channel.
- On the basis of disease type, the market is segmented into traumatic, non-traumatic, and idiopathic.
In 2023, the traumatic segment of disease type segment is expected to dominate the U.S. Osteonecrosis Market
In 2023, the traumatic segment is expected to dominate the market with 60.93% market share due to the increasing number of road accidents causing traumatic injuries causing osteonecrosis.
- On the basis of type, the market is segmented into diagnosis and treatment. In 2023, the treatment segment is expected to dominate the market with 77.30% market share.
- On the basis of stages, the market is segmented into stage 1, stage 2, stage 3, and stage 4. In 2023, the stage 2 segment is expected to dominate the market with 44.66% market share.
- On the basis of location, the market is segmented into osteonecrosis of hip/femoral head osteonecrosis, osteonecrosis of the knee, osteonecrosis of the shoulder, osteonecrosis of the talus, osteonecrosis of the lunate, osteonecrosis of the scaphoid, and others. In 2023, the osteonecrosis of hip/femoral head osteonecrosis segment is expected to dominate the market with 60.83% market share.
- On the basis of drug type, the market is segmented into branded and generic. In 2023, the branded segment is expected to dominate the market with 58.84% market share.
- On the basis of prescription, the market is segmented into over the counter drugs and prescribed drugs. In 2023, the prescribed drugs segment is expected to dominate the market with 74.69% market share.
- On the basis of gender, the market is segmented into male and female.
In 2023, the male segment in gender segment is expected to dominate the U.S. osteonecrosis market
In 2023, the male segment is expected to dominate the market with 74.69% market share due to the increasing incidence of traumatic injuries among males.
- On the basis of age, the market is segmented into children, adult, and geriatric. In 2023, the adult segment is expected to dominate the market with 69.32% market share.
- On the basis of end user, the market is segmented into hospitals, specialty clinics, orthopaedic clinics, ambulatory centers, and others. In 2023, the hospitals segment is expected to dominate the market with 52.58% market share.
- On the basis of distribution channel, the market is segmented into direct tender and retail sales. In 2023, the retail sales segment is expected to dominate the market with 63.72% market share.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in U.S. osteonecrosis market Sciegen Pharmaceuticals (U.S.), Almatica Pharma (U.S.), Dr. Reddy's Laboratories Ltd. (India), Bayer AG (Germany), Pfizer Inc. (U.S.), Haleon Group of Companies (U.K.), Zimmer Biomet (U.S.), Stryker (U.S.), Teva Pharmaceuticals USA, Inc. (Subsidiary of Teva Pharmaceutical Industries Ltd.) (U.S.), and Arthrex, Inc. (U.S.) among others.
Market Development
- In June 2023, Bayer AG's new pharmaceutical R&D strategy to accelerate breakthrough innovations. R&D strategy is poised to translate higher quality and productivity in Bayer's innovation model into long-term growth in four key focus areas with high unmet patient needs. Shifting to breakthrough innovations based on new scientific approaches, platforms, and artificial intelligence to leverage precision medicine in oncology, cardiovascular diseases, neurology & rare diseases, and immunology.
- In February 2023, Dr. Reddy's Laboratories Ltd., a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited. The acquisition will further help develop a generic segment of the company.
- In January 2023, Zimmer Biomet announced that it had reached a definitive agreement to acquire Embody, Inc., a privately-held medical device company focused on soft tissue healing, for $155 million at closing. The acquisition includes Embody's complete portfolio of collagen-based biointegrative solutions to support healing in the most challenging orthopedic soft tissue injuries – including the TAPESTRY biointegrative implant for tendon healing and TAPESTRY RC, one of the first arthroscopic implant systems for rotator cuff repair. This acquisition will help the company in its product portfolio and business expansion.
- In July 2022, the Haleon Group of Companies announced the completion of the demerger of the Consumer Healthcare business from the GSK Group to form the Haleon Group. These demerges helped the company take control of the whole consumer health business and expand it.
- In June 2022, Pfizer Inc. provided an update on its ownership interest in Haleon plc (Haleon). This newly independent company will hold the joint Consumer Healthcare business of GSK plc and Pfizer following the demerger of approximately 80% of GSK's ownership interest to GSK's shareholders. The new ownership helped in the revenue growth of the company.
For more detailed information about the U.S. osteonecrosis market report, click here – https://www.databridgemarketresearch.com/reports/us-osteonecrosis-market
